Key result
Carvedilol linked to ~69% lower recurrent MI risk vs selective beta-blockers in STEMI survivors.
Why the study?
Optimal beta-blocker selection after primary intervention for acute ST-elevation myocardial infarction is crucial, but comparative data between selective beta-blockers and carvedilol were scarce.
Does carvedilol reduce adverse clinical outcomes compared to selective β-blockers in STEMI patients treated with primary percutaneous coronary intervention?
Observational (n=1,226)
Does carvedilol reduce adverse clinical outcomes compared to selective β-blockers in STEMI patients treated with primary percutaneous coronary intervention?
Effect estimate: HR 0.305 (95% CI 0.13-0.69)
Absolute Event Rate: 1.2% vs 4.6%
p-value: p=0.005
Carvedilol may be superior to selective β-blockers for secondary prevention in STEMI patients after primary PCI, significantly reducing the risk of recurrent myocardial infarction.
No takes yet. Share an insight, caveat, or question.
May favor carvedilol for secondary prevention post-STEMI; hypothesis-generating and requires RCT confirmation.
Jang et al. (2019) conducted an observational in ST-elevation myocardial infarction (n=1,226). Carvedilol vs. Selective β-blockers was evaluated on Recurrent myocardial infarction (HR 0.305, 95% CI 0.13-0.69, p=0.005). Carvedilol use in STEMI survivors was associated with a significantly lower risk of recurrent myocardial infarction compared to selective β-blockers (HR 0.305; 95% CI 0.13-0.69; p=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: